Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
Express News | Altimmune: To File Ind Applications for Pemvidutide in up to 3 Additional Indications With First of These Ind Submissions in Q4
Express News | Altimmune Inc - End-of-Phase 2 Meeting With FDA Scheduled for November 2024
Express News | Altimmune Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash)
Institutional Investors Control 60% of Altimmune, Inc. (NASDAQ:ALT) and Were Rewarded Last Week After Stock Increased 11%
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $24
Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements
Altimmune Spikes After Presenting Data for Obesity Drug
Express News | Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%
Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Terns Stock Jumps as Weight Loss Drug Succeeds in Early Trial
Express News | Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60TH Annual Meeting of the European Association for the Study of Diabetes
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes
Weight Loss Drug Developers Slump as Eli Lilly Slashes Cost of Some Zepbound Doses
Eli Lilly, Novo Nordisk to Maintain 'Two Horse Race' in GLP-1 Weight Loss Market